Siponimod is a selective S1P1 and S1P5 agonist with EC50 of 0.39 nM and 0.98 nM, respectively. It has been approved by US FDA for the treatment of patients with active secondary progressive multiple sclerosis (SPMS).
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Neurological Disease | Sphingosine-1-phosphate receptor 1(S1PR1)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye